Goldman Sachs
PCRX icon

Goldman Sachs’s Pacira BioSciences PCRX Stock Holding History

Goldman Sachs’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-900
Closed -$28K – 5910
2018
Q1 		$28K Sell
900
-1,700
-65% -$60.5K ﹤0.01% 5612
2017
Q4 		$119K Buy
2,600
+1,200
+86% +$47.6K ﹤0.01% 5683
2017
Q3 		$53K Sell
1,400
-4,500
-76% -$181K ﹤0.01% 6243
2017
Q2 		$281K Sell
5,900
-32,800
-85% -$1.52M ﹤0.01% 5559
2017
Q1 		$1.76M Sell
38,700
-15,100
-28% -$653K ﹤0.01% 3871
2016
Q4 		$1.74M Sell
53,800
-400
-0.7% -$13.3K ﹤0.01% 3978
2016
Q3 		$1.85M Buy
54,200
+23,200
+75% +$909K ﹤0.01% 3901
2016
Q2 		$1.05M Sell
31,000
-74,500
-71% -$3.66M ﹤0.01% 4147
2016
Q1 		$5.59M Sell
105,500
-15,800
-13% -$924K ﹤0.01% 2639
2015
Q4 		$9.31M Buy
121,300
+89,900
+286% +$5.09M ﹤0.01% 2304
2015
Q3 		$1.29M Sell
31,400
-5,200
-14% -$318K ﹤0.01% 4219
2015
Q2 		$2.59M Buy
36,600
+3,300
+10% +$260K ﹤0.01% 3586
2015
Q1 		$2.96M Buy
33,300
+29,300
+733% +$2.97M ﹤0.01% 3403
2014
Q4 		$355K Sell
4,000
-5,400
-57% -$511K ﹤0.01% 5613
2014
Q3 		$911K Buy
9,400
+3,500
+59% +$340K ﹤0.01% 4704
2014
Q2 		$542K Buy
+5,900
New +$449K ﹤0.01% 5233
2014
Q1 		– Sell
-5,000
Closed -$287K – 6879
2013
Q4 		$287K Sell
5,000
-55,000
-92% -$2.89M ﹤0.01% 5724
2013
Q3 		$2.88M Buy
60,000
+10,000
+20% +$364K ﹤0.01% 3538
2013
Q2 		$1.45M Buy
+50,000
New +$1.45M ﹤0.01% 4041

Other funds holding PCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DPCM
Doma Perpetual Capital Management Miami, Florida $372M AUM 14.96% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Goldman Sachs's PCRX Position: Q1 2026 in Review

Goldman Sachs increased its Pacira BioSciences (PCRX) stake by 21% in Q1 2026, buying an estimated $5.99M and bringing the position to 1,569,916 shares worth $35.5M. The position accounts for ﹤0.01% of the portfolio, ranked #1867.

Goldman Sachs first reported a position in PCRX in Q2 2013 and has held it in 52 quarters since. The position peaked at $59M in Q2 2015. 241 funds tracked by Wall St. Rank hold PCRX as of Q1 2026.

  • Goldman Sachs held 1,569,916 shares of Pacira BioSciences worth $35.5M as of Q1 2026.
  • Goldman Sachs bought 269,529 Pacira BioSciences shares in Q1 2026, an estimated $5.99M.
  • Pacira BioSciences made up ﹤0.01% of Goldman Sachs's portfolio in Q1 2026, its #1867 holding.
  • Goldman Sachs first reported a position in Pacira BioSciences in Q2 2013 and has held it in 52 quarters since.
  • Goldman Sachs's Pacira BioSciences position peaked at $59M in Q2 2015.
  • 241 funds tracked by Wall St. Rank held Pacira BioSciences as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.